Meso Numismatics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
April 13, 2021 at 11:06 pm IST
Share
Meso Numismatics, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was USD 55,082 compared to USD 30,103 a year ago. Net loss was USD 5.895 million compared to USD 2.509 million a year ago. Basic loss per share from continuing operations was USD 0.63 compared to USD 0.47 a year ago.
Meso Numismatics, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary, Global Stem Cell Group Inc. It distributes stem cells and other regenerative based cell lines and equipment internationally and specializes in education and training physicians in regenerative medicine. It works with doctors and staff to provide products, solutions, equipment, services, and training to help them in the application of stem cell therapies. It is focused on the manufacturing and commercialization of viable cell therapy and immune support-related products. Its professional trademarked association, The International Society for Stem Cell Application (ISCCA), is a global network of medical professionals. Its flagship operation in Istanbul employs targeted combinations of exosomes, allogeneic human mesenchymal cells, and autologous bone marrow and adipose-derived stem cells to treat an array of diseases and debilitating medical conditions.
MESO NUMISMATICS, INC. 
